6533b854fe1ef96bd12ae1ee
RESEARCH PRODUCT
Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales
Antonio VenaDaniele Roberto GiacobbeNadia CastaldoAnnamaria CattelanCristina MussiniRoberto LuzzatiFrancesco G. De RosaFilippo Del PuenteClaudio Maria MastroianniAntonio CascioSergio CarbonaraAlessandro CaponeSilvia BoniChiara SepulcriMarianna MeschiariFrancesca RaumerAlessandra OlivaSilvia CorcioneMatteo BassettiFor The Ceftabuse Study Groupsubject
Nosocomial pneumonia0301 basic medicineMicrobiology (medical)medicine.medical_specialtymedicine.drug_classmedicine.medical_treatment030106 microbiologyAntibioticscarbapenem-sparing regimenBiologymedicine.disease_causeBiochemistryMicrobiologyArticleCarbapenem-sparing regimen; Ceftazidime-avibactam; ESBL-producing Enterobacterales; Nosocomial pneumonia; Pseudomonas aeruginosa03 medical and health sciences0302 clinical medicineESBL-producing EnterobacteralesCarbapenem-sparing regimenInternal medicinemedicinePharmacology (medical)030212 general & internal medicineRenal replacement therapyGeneral Pharmacology Toxicology and PharmaceuticsRisk factorAdverse effectESBL-producing Enterobacterales; Pseudomonas aeruginosa; carbapenem-sparing regimen; ceftazidime-avibactam; nosocomial pneumoniaCeftazidime-avibactamPseudomonas aeruginosaceftazidime-avibactamnosocomial pneumonialcsh:RM1-950medicine.diseaseCeftazidime/avibactamPneumonialcsh:Therapeutics. PharmacologyInfectious DiseasesEndocrinologyBacteremiaPseudomonas aeruginosaESBL-producing Enterobacteralemedicine.drugdescription
Background: Experience in real clinical practice with ceftazidime-avibactam for the treatment of serious infections due to gram&minus
year | journal | country | edition | language |
---|---|---|---|---|
2020-02-09 | Antibiotics |